San Diego, CA -- (SBWIRE) -- 05/11/2018 -- An investigation on behalf of current long-term investors in shares of Stemline Therapeutics Inc (NASDAQ:STML) was announced over potential breaches of fiduciary duties by certain officers and directors at Stemline Therapeutics Inc.

Investors who purchased shares of Stemline Therapeutics Inc (NASDAQ:STML) and currently hold any of those NASDAQ:STML shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Stemline Therapeutics Inc (NASDAQ:STML officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.

On February 3, 2017, a lawsuit was filed against Stemline Therapeutics Inc (NASDAQ:STML) over alleged securities laws violations. The plaintiff claimed that the Defendants made false and/or misleading statements and/or failed to disclose that a cancer patient in a Stemline Therapeutics Inc clinical trial tied to SL-401 died from a severe side effect on January 18, 2017, and that as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Those who purchased shares of Stemline Therapeutics Inc (NASDAQ:STML) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com